The timing of propofol administration affects the effectiveness of remote ischemic preconditioning induced cardioprotection in rats. Issue 11 (7th February 2020) - Chen, Ke
Abstract: The cardioprotection of remote ischemic preconditioning (RIPC) is abolished under propofol maintained anesthesia. Transient receptor potential vanilloid 1 (TRPV1) channel is present in the heart, and its activation could induce cardioprotection. Therefore, we tested whether the anesthetic propofol administration phase interfered with the RIPC‐induced cardioprotection, and RIPC‐induced cardioprotection via the cardiac TRPV1 channel. Male Sprague‐Dawley rats were subjected to myocardial 30 minutes of ischemia followed by 2 hours of reperfusion. RIPC consisted of three cycles of 5‐minute ischemia/reperfusion applied to a hindlimb. Propofol infusion at 12 mg/kg/h was commenced either at 10 minutes before the start of RIPC in the P‐pre + RIPC group, or immediately after myocardial ischemia at the onset of reperfusion (P‐post + RIPC) while performing RIPC. These two propofol infusion regimes were applied to another two grou bs without RIPC (P‐pre and P‐post groups). Infarct size (IS) was assessed by triphenyltetrazolium staining. Heart TRPV1 expression was detected by Western blot and immunofluorescence. RIPC significantly reduced myocardial IS compared with the control group (36.7 ± 3% versus 57.2 ± 4%; P < .01). When propofol was started before RIPC, the IS sparing effect of RIPC was completely abolished. However, propofol infusion starting immediately after myocardial ischemia did not affect RIPC‐induced cardioprotection. TRPV1 expression significant increase after RIPC, then propofol inhibited the TRPV1 activation of RIPC if given before RIPC but not after. Our results suggest that the timing of propofol administration is critical to preserve the cardioprotection of RIPC. Propofol might cancel RIPC‐induced cardioprotection via the cardiac TRPV1 receptor. Abstract : Anesthetic propofol could be given after myocardial ischemia if one wants to preserve the effectiveness of remote noninvasive limb ischemic preconditioning. Cardiac transient receptor potential vanilloid (TRPV1) is involved in the myocardial ischemia and reperfusion injury, and TRPV1 activation might mediate in remote ischemic preconditioning induced cardioprotective effects.